Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation

用于生物正交抗癌前药激活的抗体-钯缀合物

• 批准号: EP/Y024540/1
• 负责人: Asier Unciti-Broceta
• 金额: $ 25.55万
• 依托单位: University of Edinburgh
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY024540%2F1
• 关键词: Antibody; Palladium; Conjugates; Bioorthogonal; Anti

Precious metals such as palladium or gold can be implanted finely sliced into tumours with the aim of activating chemotherapeutic drugs within the cancerous tissue, thus reducing their side effects. The development of antibodies directed towards tumour surface antigens is investigated as a novel targeted strategy with the aim to promote the release of drugs in a controlled manner exclusively at tumour sites. The Unciti-Broceta Group propose the use of palladium, an abiotic metal, to develop Antibody-Palladium Conjugates (Pd-bioconjugate or Pd-Immunoconjugate) as catalytic cancer targeted antibodies in order to kill cancer cells/tumors by the localised release of clinical anticancer agents (prodrugs).

钯或金等贵金属可以被切成薄片植入肿瘤中，目的是激活癌组织内的化疗药物，从而减少其副作用。针对肿瘤表面抗原的抗体的开发作为一种新颖的靶向策略进行了研究，目的是促进药物以受控方式专门在肿瘤部位释放。 Unciti-Broceta 集团提议使用非生物金属钯来开发抗体-钯缀合物（Pd-bioconjugate 或 Pd-Immunoconjugate）作为催化癌症靶向抗体，以便通过局部释放临床抗癌药物来杀死癌细胞/肿瘤剂（前药）。